DPP4 and type 2 diabetes mellitus: Firstly, in a prospective, randomized, open-label parallel group trial, DPP4 inhibitors reversed the origination and progression of carotid AS evaluated as intima-media thickness (IMT) in T2DM individuals treated with 12 weeks of sitagliptin and vildagliptin by reducing daily inflammation and oxidative stress.